Lactobacillus casei CRL 431 administration decreases inflammatory cytokines in a diet-induced obese mouse model

Nutrition

Volumn 31, Issue 7-8, 2015, Pages 1000-1007

  Novotny Núñez, Ivanna ^a   Maldonado Galdeano, Carolina ^a,b   de Moreno de LeBlanc, Alejandra ^a   Perdigón, Gabriela ^a,b  

^a CENTRO DE REFERENCIA PARA LACTOBACILOS CERELA CONICET   (Argentina)

^b UNIVERSIDAD NACIONAL DE TUCUMÁN   (Argentina)

Author keywords

Adipocytes; Cytokines; Diet induced obesity; Liver; Probiotic; Small intestine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INFLAMMATORY CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIET SUPPLEMENTATION; FEMALE; FERMENTED MILK; INTESTINE FLUID; LACTOBACILLUS CASEI; LACTOBACILLUS CASEI CRL 431; LIPID DIET; LIVER; MACROPHAGE; MILK; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OBESITY; PRIORITY JOURNAL; SMALL INTESTINE; SUSPENSION; ADVERSE EFFECTS; ANIMAL; BAGG ALBINO MOUSE; DIET THERAPY; DISEASE MODEL; DRUG EFFECTS; FERMENTATION; IMMUNOLOGY; INFLAMMATION; METABOLISM; MICROBIOLOGY; MOUSE MUTANT; TREATMENT OUTCOME;

ADIPOCYTES; ANIMALS; CYTOKINES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FERMENTATION; INFLAMMATION; INTESTINE, SMALL; LACTOBACILLUS CASEI; LIVER; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, OBESE; MILK; PROBIOTICS; TREATMENT OUTCOME;

EID: 84955471078     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2015.02.006     Document Type: Article

References (40)

1. WHO: Obesity and overweight. Available at:. Accessed February 24, 2015. http://www.who.int/mediacentre/factsheets/fs311/en.
2. Haslam D.W., James W.P. Obesity. Lancet 2005, 366:1197-1209.
3. Romero-Corral A., Montori V.M., Somers V.K., Korinek J., Thomas R.J., Allison T.G., et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006, 368:666-678.
4. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347-355.
5. FAO/WHO. Evaluation of health and nutritional properties of powder milk and live lactic acid bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report 2001. Available at:. http://www.fao.org/es/ESN/probio/probio.htm.
6. Maldonado Galdeano C., Novotny Nunez I., de Moreno de LeBlanc A., Carmuega E., Weill R., Perdigon G. Impact of a probiotic fermented milk in the gut ecosystem and in the systemic immunity using a non-severe protein-energy-malnutrition model in mice. BMC Gastroenterol 2011, 11:64.
7. Maassen C.B., van Holten-Neelen C., Balk F., den Bak-Glashouwer M.J., Leer R.J., Laman J.D., et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine 2000, 18:2613-2623.
8. Christensen H.R., Frokiaer H., Pestka J.J. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J Immunol 2002, 168:171-178.
9. Hamad E.M., Sato M., Uzu K., Yoshida T., Higashi S., Kawakami H., et al. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Br J Nutr 2009, 101:716-724.
10. Yadav H., Jain S., Sinha P.R. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007, 23:62-68.
11. Ma X., Hua J., Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008, 49:821-830.
12. Arora T., Singh S., Sharma R.K. Probiotics: interaction with gut microbiome and antiobesity potential. Nutrition 2013, 29:591-596.
13. da Silva S.T., Dos Santos C.A., Bressan J. Intestinal microbiota, relevance to obesity and modulation by prebiotics and probiotics. Nutr Hosp 2013, 28:1039-1048.
14. Park D.Y., Ahn Y.T., Park S.H., Huh C.S., Yoo S.R., Yu R., et al. Supplementation of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One 2013, 8:e59470.
15. Chen J., Wang R., Li X.F., Wang R.L. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr 2012, 107:1429-1434.
16. Wan Y.M., Zhu Y.Q., Xia B., Luo J. Treating TNBS-induced colitis in rats with probiotics. Turk J Gastroenterol 2011, 22:486-493.
17. Chaves S., Perdigon G., de Moreno de LeBlanc A. Yoghurt consumption regulates the immune cells implicated in acute intestinal inflammation and prevents the recurrence of the inflammatory process in a mouse model. J Food Prot 2011, 74:801-811.
18. Galdeano C.M., Perdigon G. Role of viability of probiotic strains in their persistence in the gut and in mucosal immune stimulation. J Appl Microbiol 2004, 97:673-681.
19. Perdigon G., Maldonado Galdeano C., Valdez J.C., Medici M. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr 2002, 56 Suppl 4:S21-26.
20. Galdeano C.M., Perdigon G. The probiotic bacterium Lactobacillus casei induces activation of the gut mucosal immune system through innate immunity. Clin Vaccine Immunol 2006, 13:219-226.
21. Galdeano C.M., de Moreno de LeBlanc A., Vinderola G., Bonet M.E., Perdigon G. Proposed model: mechanisms of immunomodulation induced by probiotic bacteria. Clin Vaccine Immunol 2007, 14:485-492.
22. Nunez I.N., Galdeano C.M., de LeBlanc Ade M., Perdigon G. Evaluation of immune response, microbiota, and blood markers after probiotic bacteria administration in obese mice induced by a high-fat diet. Nutrition 2014, 30:1423-1432.
23. Cani P.D., Neyrinck A.M., Fava F., Knauf C., Burcelin R.G., Tuohy K.M., et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007, 50:2374-2383.
24. Castillo N.A., Perdigon G., de Moreno de Leblanc A. Oral administration of a probiotic Lactobacillus modulates cytokine production and TLR expression improving the immune response against Salmonella enterica serovar Typhimurium infection in mice. BMC Microbiol 2011, 11:177.
25. Soulard V., Roland J., Sellier C., Gruner A.C., Leite-de-Moraes M., Franetich J.F., et al. Primary infection of C57 BL/6 mice with Plasmodium yoelii induces a heterogeneous response of NKT cells. Infect Immun 2007, 75:2511-2522.
26. Ishii-Yonemoto T., Masuzaki H., Yasue S., Okada S., Kozuka C., Tanaka T., et al. Glucocorticoid reamplification within cells intensifies NF-kappaB and MAPK signaling and reinforces inflammation in activated preadipocytes. Am J Physiol Endocrinol Metab 2010, 298:E930-E940.
27. Parra P., Bruni G., Palou A., Serra F. Dietary calcium attenuation of body fat gain during high-fat feeding in mice. J Nutr Biochem 2008, 19:109-117.
28. Yudkin J.S., Yajnik C.S., Mohamed-Ali V., Bulmer K. High levels of circulating proinflammatory cytokines and leptin in urban, but not rural, Indians. A potential explanation for increased risk of diabetes and coronary heart disease. Diabetes Care 1999, 22:363-364.
29. Pickup J.C., Chusney G.D., Mattock M.B. The innate immune response and type 2 diabetes: evidence that leptin is associated with a stress-related (acute-phase) reaction. Clin Endocrinol 2000, 52:107-112.
30. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997, 40:1286-1292.
31. Khaodhiar L., Ling P.R., Blackburn G.L., Bistrian B.R. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J Parenter Enteral Nutr 2004, 28:410-415.
32. Ahmed M., Gaffen S.L. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev 2010, 21:449-453.
33. Winer S., Paltser G., Chan Y., Tsui H., Engleman E., Winer D., et al. Obesity predisposes to Th17 bias. Eur J Immunol 2009, 39:2629-2635.
34. O'Shea D., Corrigan M., Dunne M.R., Jackson R., Woods C., Gaoatswe G., et al. Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection. Int J Obes (Lond) 2013, 37:1510-1513.
35. Matarese G., Procaccini C., De Rosa V., Horvath T.L., La Cava A. Regulatory T cells in obesity: the leptin connection. Trends Mol Med 2010, 16:247-256.
36. Satoh N., Shimatsu A., Kotani K., Himeno A., Majima T., Yamada K., et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 2009, 32:1004-1008.
37. Vijay-Kumar M., Aitken J.D., Carvalho F.A., Cullender T.C., Mwangi S., Srinivasan S., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328:228-231.
38. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
39. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the toll-like receptors. Drug Discov Today 2007, 12:80-87.
40. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.